Bioversys AG partnered with Shionogi in a CHF529 million collaboration targeting multidrug-resistant lung infections using novel ansamycin antibiotics. Pusan National University engineered bacterial extracellular vesicles to selectively eradicate Staphylococcus aureus, representing a novel antibacterial strategy. In oncology, novel molecular targets such as DLK1 in adrenocortical cancer and T-cell lymphoma therapies employing new drug combinations showcase expanding immunotherapeutic approaches to challenging diseases.